Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medtronic Cardiac Rhythm and Heart Failure
The purpose of the study was to confirm the AT500 intervention pacing effectiveness data previously seen in the ASPECT clinical trial and to gather additional data to understand the effectiveness of the intervention pacing features. Specifically, the goal of the trial is to demonstrate a reduction in frequency in symptomatic atrial tachycardia/atrial fibrillation recurrence with the intervention pacing features in patients with a pacing indication and a history of atrial tachyarrhythmias with atrial pacing leads located in the region of Bachmann's Bundle.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with fast and/or slow heartbeats who are in need of dual chamber pacing (pacing in both the atria and ventricles) as determined by their doctor.
Subjects who have a history of occasional fast heartbeats originating from the upper heart chambers.
Subjects who have experienced at least two symptomatic episodes of fast heartbeats three months prior to enrollment.
Subjects that are expected to stay on the same heart medications during the length study.
You may not be if
Subjects who have permanent (chronic) or persistent (not self-terminating) atrial fibrillation (fast heartbeats originating from the upper heart chambers).
Subjects who have atrial fibrillation due to a reversible cause, i.e. electrolyte imbalance.
Subjects who are current or immediate implantable cardioverter defibrillator (ICD) recipients.
Clareo Health | Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)
